beta-1,4-Galactosyltransferase 1/B4GalT1 Antibody [Alexa Fluor® 750]

• Reactivity: Hu
• Applications: WB, IP
• Clonality: Polyclonal
• Host: Goat
• Conjugate: Alexa Fluor 750

beta-1,4-Galactosyltransferase 1/B4GalT1 Antibody [Alexa Fluor® 750] Summary

• Immunogen: Mouse myeloma cell line NS0-derived recombinant human beta -1,4‑Galactosyltransferase 1/B4GalT1 long isoform
  Gly44-Ser398
  Accession # P15291
• Specificity: Detects human beta -1,4‑Galactosyltransferase 1/B4GalT1 in direct ELISAs and Western blots.
• Source: N/A
• Isotype: IgG
• Clonality: Polyclonal
• Host: Goat
• Purity Statement: Antigen Affinity-purified

Applications/Dilutions

• Dilutions:
  • Immunoprecipitation
  • Western Blot

Packaging, Storage & Formulations

• Storage: Protect from light. Do not freeze. 12 months from date of receipt, 2 to 8 °C as supplied
• Buffer: Supplied 0.2 mg/mL in a saline solution containing BSA and Sodium Azide.

Notes

This product is provided under an agreement between Life Technologies Corporation and R&D Systems, Inc, and the manufacture, use, sale or import of this product is subject to one or more US patents and corresponding non-US equivalents, owned by Life Technologies Corporation and its affiliates. The purchase of this product conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product only in research conducted by the buyer (whether the buyer is an academic or for-profit entity). The sale of this product is expressly conditioned on the buyer not using the product or its components (1) in manufacturing; (2) to provide a service, information, or data to an unaffiliated third party for payment; (3) for therapeutic, diagnostic or prophylactic purposes; (4) to resell, sell, or otherwise transfer this product or its components to any third party, or for any other commercial purpose. Life Technologies Corporation will not assert a claim against the buyer of the infringement of the above patents based on the manufacture, use or sale of a commercial product developed in research by the buyer in which this product or its components was employed, provided that neither this product nor any of its components was used in the manufacture of such product. For information on purchasing a license to this product for purposes other than research, contact Life Technologies Corporation, Cell Analysis Business Unit, Business Development, 29851 Willow Creek Road, Eugene, OR 97402, Tel: (541) 465-8300. Fax: (541) 335-0354.

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for beta-1,4-Galactosyltransferase 1/B4GalT1 Antibody [Alexa Fluor® 750]

• 1,4- galactosyltransferase, polypeptide 1
• B4GalT1
• B4GAL-T1
• beta-1,4-galactosyltransferase 1
• Beta-1,4-GalTase 1
• Beta4Gal-T1
• betaGlcNAc beta
• CDG2D
• EC 2.4.1
• GGTB2
• GGTB2DKFZp686N19253
• glycoprotein-4-beta-galactosyltransferase 2
• GT1
• GTB
• lactose synthase
• MGC50983
• UDP-Gal
• UDP-Gal:beta-GlcNAc beta-1,4-galactosyltransferase 1
• UDP-galactose:beta-N-acetylglucosamine beta-1,4-galactosyltransferase 1

Background

beta 4GalT1 is one of seven beta 1,4 galactosyltransferases that transfer galactose in a beta 1,4 linkage to acceptor sugars including GlcNAc, and Glc, and Xyl. By sequence similarity, the beta 4GalTs form four groups: beta 4GalT1 and beta 4GalT2, beta 4GalT3 and beta 4GalT4, beta 4GalT5 and beta 4GalT6, and beta 4GalT7 (1). beta 4GalT1 is unique among the seven enzymes because it can be expressed either as membrane associated form or secreted form (2). The secreted form is restricted to lactating mammary tissues where the enzyme forms a heterodimer with alpha -lactalbumin to catalyze the synthesis of lactose (3). The membrane form can reside either in the Golgi apparatus, where it adds galactose to N-acetylglucosamine residues, or on cell surface, where it functions as a recognition molecule during a variety of cell to cell and cell to matrix interactions, by binding to specific oligosaccharide ligands on opposing cells or in the extracellular matrix (4). The two enzymatic forms result from alternate transcription initiation sites and post-translational processing (5). Defects in beta 4GalT1 are the cause of congenital disorder of glycosylation type 2D (CDG2D) (6).

        

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Bioinformatics

• Uniprot:
  • P15291()